Bisphosphonates: Mechanisms of action

Journal of Clinical Investigation

Volumn 97, Issue 12, 1996, Pages 2692-2696

  Rodan, Gideon A ^a   Fleisch, Herbert A ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; PROTEIN TYROSINE PHOSPHATASE; SQUALENE SYNTHASE; TILUDRONIC ACID;

BONE MINERAL; BONE MINERALIZATION; BONE TURNOVER; CALCIUM CELL LEVEL; CELL SURVIVAL; ENZYME INHIBITION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW;

EID: 0029884643     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118722     Document Type: Review

References (54)

1. Menschutkin, N. 1865. Ueber die Einwirkung des Chlorazetyls auf phosphorige Säure. Ann. Chem. Pharm. 133:317-320.
2. Blomen, L.J.M.J. 1995. History of bisphosphonates: Discovery and history of the non-medical uses of bisphosphonates. In Bisphosphonate on Bones. O.L.M. Bijvoet, H.A. Fleisch, R.E. Canfield, R.G.G. Russell, editors. Elsevier Science Publishers, B.V., Amsterdam. 11-124.
3. Fleisch, H., R.G.G. Russell, and M.D. Francis. 1969. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science (Wash. DC). 165:1262-1264.
4. Francis, M.D., R.G.G. Russell, and H. Fleisch. 1969. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science (Wash. DC). 165:1264-1266.
5. Fleisch, H. 1995. Bisphosphonates in bone disease. From the laboratory to the patient. The Parthenon Publishing Group. New York/London. pp. 176.
6. Jung, A., S. Bisaz, and H. Fleisch. 1973. The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals. Calcif. Tissue Res. 11:269-280.
7. Kasting, G.B., and M.D. Francis. 1992. Retention of etidronate in human, dog, and rat. J. Bone Miner. Res. 7:513-522.
8. Boulenc, X., E. Marti, H. Joyeux, C. Roques, Y. Berger, and G. Fabre. 1993. Importance of the paracellular pathway for the transport of new bisphosphonate using the human CACO-2 monolayers model. Biochem. Pharmacol. 46:1591-1600.
9. Troehler, U., J.P. Bonjour, and H. Fleisch. 1975. Renal secretion of diphosphonates in rats. Kidney Int. 8:6-13.
10. Storm, T., T. Steiniche, G. Thamsborg, and F. Melsen. 1993. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J. Bone Miner. Res. 8:199-208.
11. Boyce, R.W., C.L. Paddock, J.R. Gleason, W.K. Sietsma, and E.F. Eriksen. 1995. The effects of risedronate on canine cancellous bone remodeling: Three-dimensional kinetic reconstruction of the remodeling site. J. Bone Miner. Res. 10:211-221.
12. Ott, S.M. 1993. Clinical effects of bisphosphonates in involutional osteoporosis. J. Bone Miner. Res. 8:S597-S606.
13. Balena, R., B.C. Toolan, M. Shea, A. Markatos, E.R. Myers, S.C. Lee, E.E. Opas, J.G. Seedor, H. Klein, D. Frankenfield, et al. 1993. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J. Clin. Invest. 92:2577-2586.
14. Guenther, H.L., H.E. Guenther, and H. Fleisch. 1981. The influence of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on lysine hydroxylation and cross-link formation in rat bone, cartilage and skin collagen. Biochem. J. 196:303-310.
15. Giuliani, N., G. Girasole, M. Pedrazzoni, G. Passeri, C. Gatti, and M. Passeri. 1995. Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J. Bone Miner. Res. 10(Suppl. 1):S171. (Abstr.)
16. Gasser, A.B., D.B. Morgan, H.A. Fleisch, and L.J. Richelle. 1972. The influence of two diphosphonates on calcium metabolism in the rat. Clin. Sci. 43: 31-45.
17. 2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif. Tissue Res. 11:196-214.
18. Watts, N.B., S.T. Harris, H.K. Genant, R.D. Wasnich, P.D. Miller, R.D. Jackson, A.A. Licata, P. Ross, G.C. Woodson, M.J. Yanover, et al. 1990. Intermittent cyclical etidronate treatment of post menopausal osteoporosis. N. Engl. J. Med. 323:73-79.
19. Harris, S.T., N.B. Watts, R.D. Jackson, H.K. Genant, R.D. Wasnich, P. Ross, P.D. Miller, A.A. Licata, and C.H. Chesnut III. 1993. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am. J. Med. 95: 557-567.
20. Giannini, S., A. D'Angelo, L. Malvasi, R. Castrignano, T. Pati, R. Tronca, L. Liberto, M. Nobile, and G. Crepaldi. 1993. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone (Tarrytown). 14:137-141.
21. Reid, I.R., D.J. Wattie, M.C. Evans, G.D. Gamble, J.P. Stapleton, and J. Cornish. 1994. Continuous therapy with pamidronale, a potent bisphosphonate, in postmenopausal osteoporosis. J. Clin. Endocrinol. & Metab. 79:1595-1599.
22. Liberman, U.A., S.R. Weiss, J. Bröll, H.W. Minne, H. Quan, N.H. Bell, J. Rodriguez-Portales, R.W. Downs, Jr., J. Dequekker, M. Favus, et al. 1995. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333:1437-1443.
23. Amprino, R., and A. Engstrom. 1952. Studies on x-ray absorption and diffraction of bone tissue. Acta Anatomica. 15:1-21.
24. Hughes, D.E., B.R. MacDonald, R.G.G. Russell, and M. Gowen. 1989. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J. Clin. Invest. 83:1930-1935.
25. Schmidt, A., S.J. Rutledge, N. Endo, E.E. Opas, H. Tanaka, G. Wesolowski, C.T. Leu, Z. Huang, C. Ramachandaran, S.B. Rodan, and G.A. Rodan. 1996. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc. Natl. Acad. Sci. USA. 93:3068-3073.
26. Evans, C.E., and I.P. Braidman. 1994. Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner. 26:95-107.
27. Boonekamp, P.M., L.J.A. van der Wee-Pals, M.M.L van Wijk-van Lennep, C.W. Thesing, and O.L.M. Bijvoet. 1986. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1:27-39.
28. Cecchini, M.G., R. Felix, H. Fleisch, and P.H. Cooper. 1987. Effects of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J. Bone Miner. Res. 2:135-142.
29. Sahni, M., H.L. Guenther, H. Fleisch, P. Collin, and T.J. Martin. 1993. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest. 91:2004-2011.
30. Nishikawa, M., T. Akatsu, Y. Katayama, Y. Yasutomo, S. Kado, N. Kugai, M. Yamamoto, and N. Nagata. 1996. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone (Tarrytown). 18:9-14.
31. Vitté, C., H. Fleisch, and H.L. Gucnther. 1996. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 137:2324-2333.
32. Parfitt, A.M., G.R. Mundy, G.D. Roodman, D.E. Hughes and B.F. Boyce. 1996. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J. Bone Miner. Res. 11:150-159.
33. Murakami, H., N. Takahashi, T. Sasaki, N. Udagawa, S. Tanaka, I. Nakamura, D. Zhang, A. Barbier, and T. Suda. 1995. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone (Tarrytown). 17:137-144.
34. Sato, M., and W. Grasser. 1990. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J. Bone Miner Res. 5: 31-40.
35. Plasmans, C.M.T., P.H.K. Jap, W. Kuypers, and T.J.J. Slooff. 1980. Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif. Tissue Int. 32:247-256.
36. Sato, M., W. Grasser, N. Endo, R. Akins, H. Simmons, D.D. Thompson, E. Golub, and G.A Rodan. 1991. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88: 2095-2105.
37. Fast, D.K., R. Felix, C. Dowse, W.F. Neuman, and H. Fleisch. 1978. The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem. J. 172:97-107.
38. 14C 1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif. Tissue Int. 36:108-113.
39. 3H-etidronate in rat and mouse bones. J. Bone Miner. Res. 10(Suppl. 1):S250. (Abstr.)
40. Azuma, Y., H. Sato, Y. Oue, K. Okabe, T. Ohta, M. Tsuchimoto, and M. Kiyoki. 1995. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemic models. Bone (Tarrytown). 16:235-245.
41. Hughes, D.E., K.R. Wright, H.L. Uy, A. Sasaki, T. Yoneda, G.D. Roodman, G.R. Mundy, and B.F. Boyce. 1995. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10:1478-1487.
42. Shinoda, H., G. Adamek, R. Felix, H. Fleisch, R. Schenk, and P. Hagan. 1983. Structure-activity relationships of various bisphosphonates. Calcif. Tissue Int. 35:87-99.
43. Duncan, R., and M.K. Pratten. 1985. Pinocytosis: mechanism and regulation. In Mononuclear Phagocytes: Physiology and Pathology. Research Monographs in Cell and Tissue Physiology 11. J.T. Dingle and J.L. Gordon, editors. Elsevier Science Publishers, B.V., Amsterdam/New York. 27-51.
44. Adami, S., A.K. Bhalla, R. Dorizzi, F. Montesanti, S. Rosini, G. Salvagno, and V. Lo Cascio. 1987. The acute-phase response after bisphosphonate administration. Calcif. Tissue Int. 41:325-331.
45. Schweitzer, D.H., M. Oostendorp-van de Ruit, G. van der Pluijm, C.W.G.M. Löwik, and S.E. Papapoulos. 1995. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J. Bone Miner. Res. 10:956-962.
46. Rogers, M.J., D.J. Watts, R.G.G. Russell, X. Ji, X. Xiong, G.M. Blackburn, A.V. Bayless, and F.H. Ebetino. 1994. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold dictostelium discoideum. J. Bone Miner. Res. 9:1029-1039.
47. Zimolo, Z., G. Wesolowski, and G.A. Rodan. 1995. Acid extrusion is induced by osteoclast attachment to bone: inhibition by alendronate and calcitonin. J. Clin. Invest. 96:2277-2283.
48. + ATPase. Bone (Tarrytown). 16: 166S. (Abstr.)
49. Felix, R., R.G.G. Russell, and H. Fleisch. 1976. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim. Biophys. Acta. 429:429-438.
50. Ciosek, C.P., Jr., D.R. Magnin, T.W. Harrity, J.V.H. Logan, J.K. Dickson, Jr., E.M. Gordon, K.A. Hamilton, K.G. Jolibois, L.K. Kunselman, R.M. Lawrence, et al. 1993. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J. Biol. Chem. 268:24832-24837.
51. Endo, N., S.J. Rutledge, E.E. Opas, R. Vogel, G.A. Rodan, and A. Schmidt. 1996. Human protein tyrosine phosphalase-σ: alternative splicing and inhibition by bisphosphonates. J. Bone Min. Res. 11(4):535-543.
52. c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. 90:1622-1627.
53. Cooper, J.A., and B. Howell. 1993. The when and how of src regulation. Cell. 73:1051-1054.
54. Schmidt, A., S.J. Rutledge, E.E. Opas, G. Wesolowski, C.T. Leu, S.B. Rodan, and G.A. Rodan. 1995. Protein tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Mol. Biol. Cell. 6(Suppl.):136a. (Abstr.)